J. Oates

5.2k citations

25 papers · 3.6k indexed · 2 hit papers · h-index 14

Gastroenterology top 0.5%
Oncology top 1%
- Colorectal Cancer Treatments and Studies 15
- Colorectal Cancer Surgical Treatments 9
- Colorectal Cancer Screening and Detection 3
Pulmonary and Respiratory Medicine top 1%
- Gastric Cancer Management and Outcomes 11
Surgery top 2%
- Colorectal and Anal Carcinomas 8
- Esophageal Cancer Research and Treatment 4
Geriatrics and Gerontology top 2%
Radiology, Nuclear Medicine and Imaging
- Radiomics and Machine Learning in Medical Imaging 2
Cancer Research
- Cancer Genomics and Diagnostics 2

Co-authors: David Cunningham A. Norman Timothy Iveson Naureen Starling Francis Daniel Sheela Rao M. Nicolson Gary Middleton
Cited by: Gastroenterology Oncology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (11 papers)European Journal of Cancer (3 papers)Annals of Oncology (3 papers)
Partner nations: United Kingdom Spain Sweden

In The Last Decade

J. Oates

25 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by J. Oates

Since Specialization

Citations

This map shows the geographic impact of J. Oates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Oates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Oates more than expected).

Fields of papers citing papers by J. Oates

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Oates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Oates. The network helps show where J. Oates may publish in the future.

Co-authorship network

The 25 scholars most cited alongside J. Oates, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Oates Line = papers co-authored together J. Oates links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Multiplatform assay to classify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples into molecular subtypes with mutational profiles Annals of Oncology ·Elisa Fontana,Chanthirika Ragulan,David Cunningham,Sanna Hulkki-Wilson,Francesco Sclafani,Gift Nyamundanda,Katherine Eason,Ruwaida Begum,Irene Chong,Clare Peckitt,Maria Antonietta Bali,J. Oates,David Watkins,Shuan Rao,Michael Hubank,Andrew Wotherspoon,Nicola Valeri,Ian Chau,Naureen Starling,Anguraj Sadanandam	2017	1
2	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer Annals of Oncology ·Francesco Sclafani,Gina Brown,David Cunningham,Andrew Wotherspoon,Diana Tait,Clare Peckitt,Jessica Evans,Shun Yu,Larissa Mendes,Josep Tabernero,Bengt Glimelius,Andrés Cervantes,Janet Thomas,Ruwaida Begum,J. Oates,Ian Chau	2016	54
3	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial International Journal of Radiation OncologyBiologyPhysics ·Francesco Sclafani,Clare Peckitt,David Cunningham,Diana Tait,J. Giralt,Bengt Glimelius,Susana Roselló,Andrew Bateman,Tamas Hickish,Josep Tabernero,Janet Thomas,Gina Brown,J. Oates,Ian Chau	2015	18
4	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial. Journal of Clinical Oncology ·Francesco Sclafani,Ian Chau,David Cunningham,Andrea Lampis,Jens C. Hahne,Chiara Braconi,Clare Peckitt,David González,NV Nakum,Jaume Capdevila,Bengt Glimelius,Andrés Cervantes,Ruwaida Begum,Gina Brown,Diana Tait,Andrew Wotherspoon,U-Chang Kim,A. G. Kim,J. Oates,Nicola Valeri	2015	1
5	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial JNCI Journal of the National Cancer Institute ·Francesco Sclafani,David González,David Cunningham,Sanna Hulkki Wilson,Clare Peckitt,Josep Tabernero,Bengt Glimelius,Andrés Cervantes,Alice Dewdney,Andrew Wotherspoon,Gina Brown,Diana Tait,J. Oates,Ian Chau	2014	37
6	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC). Journal of Clinical Oncology ·Francesco Sclafani,Clare Peckitt,David Cunningham,Jessica Evans,Gina Brown,Josep Tabernero,Bengt Glimelius,Andrés Cervantes,Diana Tait,Andrew Wotherspoon,Janet Thomas,J. Oates,Ian Chau	2014	5
7	FcγRIIaandFcγRIIIaPolymorphisms and Cetuximab Benefit in the Microscopic Disease Clinical Cancer Research ·Francesco Sclafani,David González de Castro,David Cunningham,Sanna Hulkki Wilson,Clare Peckitt,Jaume Capdevila,Bengt Glimelius,Susana Roselló,Andrew Wotherspoon,Gina Brown,Diana Tait,Ruwaida Begum,Janet Thomas,J. Oates,Ian Chau	2014	8
8	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC). Journal of Clinical Oncology ·Francesco Sclafani,David González,David Cunningham,NV Nakum,Clare Peckitt,Josep Tabernero,Bengt Glimelius,Andrés Cervantes,Andrew Wotherspoon,Gina Brown,Diana Tait,J. Oates,Ian Chau	2014	3
9	HER-2 in high risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Journal of Clinical Oncology ·Francesco Sclafani,Amitesh Roy,Ian Chau,Andrew Wotherspoon,Clare Peckitt,Alice Dewdney,J. Oates,David Cunningham	2013	2
10	Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C) Journal of Clinical Oncology ·Alice Dewdney,David Cunningham,Josep Tabernero,Jaume Capdevila,Bengt Glimelius,Andrés Cervantes,Diana Tait,Gina Brown,Andrew Wotherspoon,David González de Castro,Yu Jo Chua,Rachel Wong,Yolanda Barbáchano,J. Oates,Ian Chau	2012	287
11	A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma British Journal of Cancer ·Naureen Starling,Alicia Okines,David Cunningham,William Allum,Andrew Wotherspoon,Shreya Gowda,J N Thompson,Janet Thomas,Gina Brown,Angela M. Riddell,Amoon Mohammed Ali Albatool,S. Ashley,J. Oates,Ian Chau	2009	20
12	Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in Assessing Prognosis and Predicting First-Line Treatment Efficacy in Follicular Lymphoma Patients Acta Haematologica ·Vincenzo Formica,A. Norman,David Cunningham,A. Wotherspoon,J. Oates,Gun Oh Chong	2009	13
13	Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancerbreakdown → New England Journal of Medicine ·David Cunningham,Naureen Starling,Sheela Rao,Timothy Iveson,M. Nicolson,Fareeda Y. Coxon,Gary Middleton,Francis Daniel,J. Oates,A. Norman	2008	1727
14	Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer Journal of Clinical Oncology ·Ian Chau,Gina Brown,David Cunningham,Diana Tait,Andrew Wotherspoon,A. Norman,Niall C. Tebbutt,Mark Hill,Paul J. Ross,Alison Massey,J. Oates	2006	324
15	CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials British Journal of Cancer ·N. Maisey,A. Norman,A Hill,Alison Massey,J. Oates,David Cunningham	2005	125
16	Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer European Journal of Cancer ·Ian Chau,A. Norman,David Cunningham,Timothy Iveson,Mark Hill,Tamas Hickish,F. Lofts,Duncan I. Jodrell,Andrew Webb,Diana Tait,Paul J. Ross,John Fite,J. Oates	2005	18
17	Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy Journal of Clinical Oncology ·Anke Dewert,Ian Chau,A. R. Norman,Maria Sonia L. Silva,Ferris Shahrestani,Gary Middleton,Mark Hill,Paul J. Ross,J. Oates,David Cunningham	2004	1
18	305 Twelve weeks of neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation (CRT) and total mesorectal excision (TME) in MRI defined poor risk locally advanced rectal cancer resulted in promising tumour regression and rapid symptomatic relief European Journal of Cancer Supplements ·Ian Chau,David Cunningham,Marie‐Isabel Theuwis,Gina Brown,Niall C. Tebbutt,Maureen V. Hill,Andrew Wotherspoon,Alyson Norman,Alison Massey,J. Oates	2003	9
19	Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?breakdown → European Journal of Cancer ·Jervoise Andreyev,A. Norman,J. Oates,David Cunningham	1998	603
20	A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer Annals of Oncology ·Paul J. Ross,A. Norman,David Cunningham,Andrew Webb,Timothy Iveson,Anwar R. Padhani,J Prendiville,Maggie Watson,Alison Massey,Răzvan Popescu,J. Oates	1997	107

About J. Oates

J. Oates is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Internal Medicine and Gastroenterology, having authored 25 papers that have together received 3.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (11 papers), Colorectal Cancer Surgical Treatments (9 papers), Colorectal and Anal Carcinomas (8 papers), Esophageal Cancer Research and Treatment (4 papers), Colorectal Cancer Screening and Detection (3 papers), Radiomics and Machine Learning in Medical Imaging (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Gastroenterology (587 citations), Oncology (2.1k citations), Pulmonary and Respiratory Medicine (1.9k citations), Surgery (1.7k citations) and Geriatrics and Gerontology (131 citations). J. Oates has collaborated with scholars based in United Kingdom, Spain and Sweden. Frequent co-authors include David Cunningham, A. Norman, Timothy Iveson, Naureen Starling, Francis Daniel, Sheela Rao, M. Nicolson, Gary Middleton, Fareeda Y. Coxon and A. Norman. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, British Journal of Cancer and Acta Haematologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact